A Single-arm, Open-label, Multicenter, Phase Ib/II Clinical Trial of CVL237 Tablets in Combination With Serplulimab Injection for the Treatment of Advanced Solid Tumors With PTEN Loss or Low Expression
Convalife (Shanghai) Co., Ltd.
Convalife (Shanghai) Co., Ltd.
Kaiser Permanente
Unity Health Toronto
Cogent Biosciences, Inc.
Second Life Therapeutics
Beaumont Hospital
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd
Universidade Federal de Pernambuco
Danatlas Pharmaceuticals Co., Ltd
Sun Yat-sen University